A Phase I Trial of Bevacizumab, Temsirolimus Alone and in Combination With Valproic Acid or Cetuximab in Patients With Advanced Malignancy and Other Indications
Phase of Trial: Phase I
Latest Information Update: 03 Apr 2018
At a glance
- Drugs Bevacizumab (Primary) ; Temsirolimus (Primary) ; Cetuximab; Valproic acid
- Indications Cancer
- Focus Adverse reactions
- 26 Mar 2018 Planned End Date changed from 1 Mar 2020 to 1 Mar 2021.
- 09 Aug 2012 Planned number of patients changed from 228 to 216 as reported by ClinicalTrials.gov.
- 20 Mar 2012 Status changed from not yet recruiting to recruiting as reported by M.D. Anderson Cancer Center record.